Comparison of allergy prevalence between brimonidine/timolol fixed combination and 0.15% brimonidine in glaucoma patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Eun Jung | - |
dc.contributor.author | Chun, Yeoun Sook | - |
dc.date.available | 2019-03-08T06:55:50Z | - |
dc.date.issued | 2018-05 | - |
dc.identifier.issn | 0378-6471 | - |
dc.identifier.issn | 2092-9374 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3193 | - |
dc.description.abstract | Purpose: To compare the allergy prevalence and clinical manifestations of 0.2% brimonidine/0.5% timolol fixed combination (BTFC) and 0.15% brimonidine in Korean patients with glaucoma. Methods: We retrospectively analyzed the medical records of 196 glaucoma patients treated with BTFC and 234 glaucoma patients treated with 0.15% brimonidine. We compared sex, age, type of glaucoma, treatment period, allergy history, onset time of ocular allergy and clinical characteristics of allergy in the two groups. Results: Ocular allergy percentages 10.14% in the BTFC group and 22.02% in the 0.15% brimonidine group, and the risk of allergy was approximately 0.4 times lower in patients using BTFC (hazard ratio = 2.5, p = 0.009). The BTFC group developed ocular allergy at a mean of 20.5 months (range: 1.7–51.1 months), and the 0.15% brimonidine group developed ocular allergy at a mean of 7.7 months (range: 0.4–50.8 months). In the BTFC group, 50% of the ocular allergy occurred within 15 months, and within 5 months in the 0.15% brimonidine group. Clinical characteristics of brimonidine allergy involved two types of conjunctival follicles and conjunctival papillae, but there were no significant differences in incidence according to allergy type (p = 0.566). Conclusions: The prevalence of ocular allergy in the BTFC group was lower than that in the 0.15% brimonidine group in Korean patients with glaucoma. The results of this study are expected to be useful for patient education and compliance improvement using brimonidine. © 2018 The Korean Ophthalmological Society. | - |
dc.format.extent | 8 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | Korean Ophthalmological Society (KOS) | - |
dc.title | Comparison of allergy prevalence between brimonidine/timolol fixed combination and 0.15% brimonidine in glaucoma patients | - |
dc.title.alternative | 녹내장에서 브리모니딘/티몰롤 복합제제와 0.15% 브리모니딘 사용 시 알레르기 발생률의 비교 | - |
dc.type | Article | - |
dc.identifier.doi | 10.3341/jkos.2018.59.5.451 | - |
dc.identifier.bibliographicCitation | Journal of Korean Ophthalmological Society, v.59, no.5, pp 451 - 458 | - |
dc.identifier.kciid | ART002346613 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000471838700009 | - |
dc.identifier.scopusid | 2-s2.0-85048100769 | - |
dc.citation.endPage | 458 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 451 | - |
dc.citation.title | Journal of Korean Ophthalmological Society | - |
dc.citation.volume | 59 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | 0.15% brimonidine | - |
dc.subject.keywordAuthor | 0.2% brimonidine/0.5% timolol fixed combination | - |
dc.subject.keywordAuthor | Glaucoma | - |
dc.subject.keywordAuthor | Korean | - |
dc.subject.keywordAuthor | Ocular allergy | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.